FGFR2 and pancreatic neoplasm: Dovitinib, a potent FGFR multikinase inhibitor, achieved a preclinical anticancer effect in pancreatic cancers with heightened FGFR signaling, suggesting that the efficacy may be most pronounced in cancer cells overexpressing FGFR2.